Related references
Note: Only part of the references are listed.The road to biosimilars in rare diseases - ongoing lessons from Gaucher disease
Guillermo Drelichman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
Christine Serratrice et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease
Fabio Nascimbeni et al.
LIVER INTERNATIONAL (2020)
Gaucher Disease in Bone: From Pathophysiology to Practice
Derralynn Hughes et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Are there biosimilar orphan drugs for Gaucher disease? An overview in Mexico
G. Castaneda-Hernandez et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2019)
Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis?
Sabrina Mariani et al.
ACTA HAEMATOLOGICA (2018)
Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center
Espen Mendelsohn et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy
Neal J. Weinreb et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
Hepatocellular carcinoma in Gaucher disease: an international case series
Martine Regenboog et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2018)
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease
Fabio Nascimbeni et al.
MOLECULAR GENETICS AND METABOLISM (2018)
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
Pramod K. Mistry et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals
Kai Uwe Chow et al.
RADIOLOGY (2016)
The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease
Carla E. M. Hollak et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)
Neal J. Weinreb et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Gaucher Disease and Bone Manifestations
Gemma Marcucci et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies
Erik von Elm et al.
INTERNATIONAL JOURNAL OF SURGERY (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
Neal J. Weinreb et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
Divair Doneda et al.
NUTRITION & METABOLISM (2013)
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years
Carla E. M. Hollak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply
Ari Zimran et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher disease
Bryn D. Webb et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Enzyme replacement therapy drug holiday: Results from an unexpected shortage of an orphan drug supply in Australia
Jack Goldblatt et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy
Patrick B. Deegan et al.
MEDICINE (2011)
Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis
Pramod K. Mistry et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1
Gregory A. Grabowski et al.
GENETICS IN MEDICINE (2009)
A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase
Neal Weinreb et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy
A. Langeveld et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
T. M. Cox et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature
M. Biegstraaten et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1
Hans Andersson et al.
PEDIATRICS (2008)
The long-term international safety experience of imiglucerase therapy for Gaucher disease
Kathryn Starzyk et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease
Derralynn Hughes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Quality of life related to type 1 Gaucher disease:: Spanish experience
P Giraldo et al.
QUALITY OF LIFE RESEARCH (2005)
Therapeutic goals in the treatment of Gaucher disease
GM Pastores et al.
SEMINARS IN HEMATOLOGY (2004)
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry
NJ Weinreb et al.
AMERICAN JOURNAL OF MEDICINE (2002)
The Gaucher registry -: Demographics and disease characteristics of 1698 patients with Gaucher disease
J Charrow et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
